This activity is supported by an educational grant from Novo Nordisk.
On-demand CE Webinar
Scott Kahan, MD, MPH
Strategies to Overcome and Prevent (STOP) Obesity Alliance
George Washington University
National Center for Weight and Wellness
More than two-thirds of adults and one in three children in the United States are currently defined as overweight or obese. The high prevalence of obesity, the associated medical complications, and high health care costs make obesity a serious public health issue. Healthcare provider awareness may lead to increased screening of patients at risk, increased prescribing of medications to prevent or treat obesity, and recommendations of lifestyle modifications for those who are obese. This webinar will discuss the current treatment recommendations and appropriate selection of pharmacologic options to treat and prevent obesity, as well as the role that nurse practitioners can play to improve obesity management.
At the completion of this activity, the participant will be able to:
Statement of Need:
Identify the prevalence of obesity and associated co-morbid conditions and the need to screen for them
Examine current treatment guidelines including the development of lifestyle management and pharmacotherapy treatment plans
Explain how to effectively utilize available pharmacotherapies for obesity, including appetite suppressants and agents that reduce nutrient absorption
Obesity is a serious, chronic health problem and as one of the primary points of contact in the healthcare setting, nurse practitioners have an opportunity to screen patients, identify those who are overweight or obese, and initiate treatment plan. With several pharmacotherapies available for short-term and long-term weight management, understanding the efficacy, safety, and related prescribing regulations allows for the selection of an appropriate therapy for the patient.
Length of Webinar:
January 31, 2017
January 31, 2018
How to Obtain Credit
To receive credit, participants must complete the online pretest, view the activity in its entirety, and complete the online post-test and activity evaluation form. After completing the online assessment tests, and completing the activity evaluation form, participants may request credit. All participants must request credit before January 31, 2018. CE credit will not be issued after this date.
Global Education Group is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners: AANP Provider Number 110121. This program has been approved for 1.0 contact hours of continuing education (which includes 0.1 hours of pharmacology). Activity ID# 2215E.
This activity was planned in accordance with AANP CE Standards and Policies.
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Scott Kahan, MD, MPH has the following relevant financial relationships with commercial interest to disclose:
Consultant: Novo Nordisk, Takeda, Orexigen, and Vivus
Textbook Royalties: Johns Hopkins University Press, Lippincott Williams & Wilkins
Honoraria: Harvard Medical School, Institute of Medicine, Medscape, WebMD, Vindico Medical Education, Wake Forrest University, Obesity Action Coalition, Academy of Nutrition and Dietetics, European Association for the Study of Obesity, Obesity Medicine, Association, and Women in Government
The following contributors have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education
—David Heckard; Maryjo Dixon, RPh; Donna Fausak
Global Education Group
Kristen Delisi, NP, Amanda Glazar, PhD, Andrea Funk, Laura Gilsdorf
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global), Physicians Education Resource (PER) and ArcMesa do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Required: Windows® 7, Vista, XP, 2003 Server or 2000
Required: Mac OS® X 10.4.11 (Tiger®) or newer
For questions about this Internet activity, please contact: firstname.lastname@example.org